By Rishika Sadam May 13 (Reuters) - U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also ...
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly ...
Eli-Lilly has launched India’s first disease-modifying Alzheimer’s drug, donenemab, under the brand name Lormalzi. Approved by the CDSCO in 2025, the treatment aims to slow cognitive decline in ...
Eli Lilly launches Lormalzi in India, a once-monthly Alzheimer's therapy for mild impairment. It targets amyloid plaques to ...
1d
Alzheimer’s Treatment Drug Launched In India At Nearly ₹1 Lakh Per Dose, Here's All You Need To Know
Priced at Rs 91,688 for a 350 mg vial, the prescription-only intravenous therapy is to be administered once a month for up to ...
(Reuters) - Eli Lilly and Co on Saturday said its experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32% compared with a placebo in a mid-stage trial of ...
This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved ...
India Today on MSN
India gets first Alzheimer's drug amid debate over real benefits
Eli Lilly has launched Lormalzi, its donanemab treatment for early Alzheimer's disease, in India. The rollout opens a new ...
Unlike existing treatments, Lormalzi is described as the first once-monthly amyloid plaque-targeting therapy in India, with a dosing approach that can be adjusted based on how much plaque reduction is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results